Compare MYRG & CORT Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
| Metric | MYRG | CORT |
|---|---|---|
| Founded | 1891 | 1998 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Water Sewer Pipeline Comm & Power Line Construction | Biotechnology: Pharmaceutical Preparations |
| Sector | Industrials | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 3.9B | 3.7B |
| IPO Year | 2008 | 2001 |
| Metric | MYRG | CORT |
|---|---|---|
| Price | $338.95 | $46.50 |
| Analyst Decision | Buy | Buy |
| Analyst Count | 8 | 5 |
| Target Price | ★ $262.43 | $96.50 |
| AVG Volume (30 Days) | 230.0K | ★ 956.9K |
| Earning Date | 04-29-2026 | 04-30-2026 |
| Dividend Yield | N/A | N/A |
| EPS Growth | ★ 311.48 | N/A |
| EPS | ★ 7.53 | 0.82 |
| Revenue | ★ $1,531,169,000.00 | $761,407,000.00 |
| Revenue This Year | $11.87 | $26.08 |
| Revenue Next Year | $8.48 | $26.98 |
| P/E Ratio | ★ $44.27 | $56.95 |
| Revenue Growth | N/A | ★ 12.79 |
| 52 Week Low | $131.96 | $28.66 |
| 52 Week High | $349.15 | $91.00 |
| Indicator | MYRG | CORT |
|---|---|---|
| Relative Strength Index (RSI) | 65.95 | 65.55 |
| Support Level | $255.59 | $32.40 |
| Resistance Level | N/A | $47.06 |
| Average True Range (ATR) | 10.35 | 1.58 |
| MACD | 0.38 | 0.05 |
| Stochastic Oscillator | 73.83 | 86.39 |
MYR Group Inc is a U.S.-based holding company that provides specialty electrical construction services through its subsidiaries. The company operates through two segments. The transmission and distribution segment provides designing, engineering, procurement, construction, upgrade, maintenance, and repair services on transmission and distribution networks and substation facilities. The commercial and industrial segment provides services such as the design, installation, maintenance, and repair of commercial and industrial wiring, installation of traffic networks, and the installation of bridges. MYR Group generates the majority of its sales from the United States and Canada.
Corcept Therapeutics Inc is a commercial-stage pharmaceutical company engaged in the discovery and development of medications that treat severe metabolic, oncologic and neuropsychiatric disorders by modulating the effect of the hormone cortisol. The company's compounds are being evaluated in clinical trials as potential treatments for a variety of serious disorders - hypercortisolism, advanced ovarian cancer, prostate cancer, ALS, and MASH.